MNKD MannKind Corporation

1.88
-0.03  -2%
Previous Close 1.91
Open 1.95
52 Week Low 0.8
52 Week High 2.48
Market Cap $430,848,838
Shares 229,174,914
Float 227,025,435
Enterprise Value $502,673,584
Volume 1,154,031
Av. Daily Volume 2,282,476
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
AFREZZA
Type 1/2 diabetes
Approved
Approved
Approved June 27, 2014.

Latest News

  1. WESTLAKE VILLAGE, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diabetes and orphan lung diseases, announced today that it will be participating at upcoming conferences. Presenting from the Company will be its Chief Executive Officer, Michael Castagna, PharmD. 

    • H.C. Wainwright 22nd Annual Global Investment Conference - Fireside Chat on Monday, September 14, 2020 at 3:30 pm (EDT)
    • 2020 Cantor Global Virtual Healthcare Conference - Fireside Chat on Tuesday, September 15, 2020 at 8:40 am - 9:10 am (EDT) 
    • Oppenheimer Fall Healthcare Life Sciences & MedTech Summit – Fireside Chat on Monday, September 21, 2020…

    WESTLAKE VILLAGE, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diabetes and orphan lung diseases, announced today that it will be participating at upcoming conferences. Presenting from the Company will be its Chief Executive Officer, Michael Castagna, PharmD. 

    • H.C. Wainwright 22nd Annual Global Investment Conference - Fireside Chat on Monday, September 14, 2020 at 3:30 pm (EDT)
    • 2020 Cantor Global Virtual Healthcare Conference - Fireside Chat on Tuesday, September 15, 2020 at 8:40 am - 9:10 am (EDT) 
    • Oppenheimer Fall Healthcare Life Sciences & MedTech Summit – Fireside Chat on Monday, September 21, 2020 at 10:50 am - 11:30 am (EDT)

    Interested parties can access a link to the live webcast of the presentations from the News & Events section of the Company's website at http://www.mannkindcorp.com. The webcast replay will remain available for 14 days following the live presentation.

    About MannKind Corporation

    MannKind Corporation (NASDAQ:MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.

    Company Contact:

    818-661-5000

    Source: MannKind Corporation

    Primary Logo

    View Full Article Hide Full Article
  2. WESTLAKE VILLAGE, Calif., Aug. 31, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that Kevin Kaiserman, MD, has joined the company as Vice President, Medical Affairs and Safety and will assume full responsibility for leading MannKind's medical affairs, field medical activities, safety, and pediatrics initiatives. Dr. Kaiserman will report directly to Michael Castagna, Chief Executive Officer and will be based in MannKind's Westlake Village, California headquarters.

    "As a board-certified pediatric endocrinologist, Kevin brings significant expertise in the field of type 1 diabetes, and is an integral addition to MannKind as we expand our medical affairs capabilities and advance our pediatrics program," said Michael…

    WESTLAKE VILLAGE, Calif., Aug. 31, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that Kevin Kaiserman, MD, has joined the company as Vice President, Medical Affairs and Safety and will assume full responsibility for leading MannKind's medical affairs, field medical activities, safety, and pediatrics initiatives. Dr. Kaiserman will report directly to Michael Castagna, Chief Executive Officer and will be based in MannKind's Westlake Village, California headquarters.

    "As a board-certified pediatric endocrinologist, Kevin brings significant expertise in the field of type 1 diabetes, and is an integral addition to MannKind as we expand our medical affairs capabilities and advance our pediatrics program," said Michael Castagna, Chief Executive Officer of MannKind. "His deep expertise in continuous glucose monitoring and insulin delivery, coupled with his lengthy experience in educating the endocrinology community, will be instrumental in moving our medical initiatives forward and supporting the effort to expand our Afrezza user base."

    Dr. Kaiserman's career includes over 25 years of experience in pediatric endocrinology. For the past 14 years, he has provided clinical management and research for type 1 diabetes patients at his private practice, SoCal Diabetes. Prior to entering private practice, Dr. Kaiserman was a Clinical Associate Professor of Pediatrics and Medical Director of the Clinical Diabetes Program at Children's Hospital Los Angeles and the University of Southern California, Keck School of Medicine. Dr. Kaiserman earned his medical degree from Eastern Virginia Medical School in Norfolk. He completed his internship and residency in the Department of Pediatrics and his fellowship in the Division of Pediatric Endocrinology at the University of California, Los Angeles.

    A renowned speaker and thought leader in the field of diabetes, Dr. Kaiserman has participated in numerous publications and research studies. He is board certified in pediatric endocrinology and is a member of the American Diabetes Association, the Pediatric Endocrine Society, and the Board of Directors of the Los Angeles Chapter of the Juvenile Diabetes Research Foundation. Dr. Kaiserman is the Medical Director of Camp Conrad-Chinnock, a camping program for children and adolescents with diabetes, and serves on the Board of Directors for the international Diabetes Education and Camping Association.

    "I'm thrilled to join MannKind during this exciting time of expansion," said Dr. Kaiserman. "Afrezza is a novel treatment option that provides mealtime control and flexibility for adults living with type 1 and type 2 diabetes. I look forward to working with my colleagues across the country to study this therapy in pediatrics and hope to bring the benefits of Afrezza to children and adolescents living with diabetes. I've seen the rapid rate of innovation around diabetes management over the past decades and am honored to lead the medical team at a company that is changing the way people living with diabetes take control of their health."  

    About MannKind Corporation

    MannKind Corporation (NASDAQ:MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide.  MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.

    Forward-Looking Statements

    This press release contains forward-looking statements that involve risks and uncertainties. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind's current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties detailed in MannKind's filings with the SEC. For a discussion of these and other factors, please refer to MannKind's annual report on Form 10-K for the year ended December 31, 2019 as well as MannKind's other filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.

    Company Contact:

    818-661-5000



    Primary Logo

    View Full Article Hide Full Article
  3. WESTLAKE VILLAGE, Calif., Aug. 07, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diabetes and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, will participate in a Fireside Chat at the BTIG Virtual Biotechnology Conference 2020 on Tuesday, August 11, 2020 at 2:00 pm (ET). Interested parties can access a link to the live webcast of the presentation from the Events & Presentations section of the Company's website at http://www.mannkindcorp.com. The webcast replay will remain available for 14 days following the live presentation.

    About MannKind Corporation

    MannKind Corporation…

    WESTLAKE VILLAGE, Calif., Aug. 07, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diabetes and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, will participate in a Fireside Chat at the BTIG Virtual Biotechnology Conference 2020 on Tuesday, August 11, 2020 at 2:00 pm (ET). Interested parties can access a link to the live webcast of the presentation from the Events & Presentations section of the Company's website at http://www.mannkindcorp.com. The webcast replay will remain available for 14 days following the live presentation.

    About MannKind Corporation

    MannKind Corporation (NASDAQ:MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.

    Company Contact:

    818-661-5000

    Primary Logo

    View Full Article Hide Full Article
    • 2Q 2020 Afrezza Net Revenue of $7.0 million; +15% vs. 2Q 2019
    • 1H 2020 Afrezza Net Revenue of $15.0 million; +35% vs. 1H 2019
    • Cash and cash equivalents of $63.2 million at June 30, 2020
    • Non-GAAP cash used in operating activities decreased by 37% vs. 1H 2019
    • Chief Commercial Officer, Alejandro Galindo, joined MannKind

    WESTLAKE VILLAGE, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the quarter and six months ended June 30, 2020.

    "I am proud of how our employees pulled together during these uncertain times and innovated as a team to minimize the impact of the COVID-19 pandemic on our business during the second quarter," said Michael Castagna, Chief Executive Officer.  "A small…

    • 2Q 2020 Afrezza Net Revenue of $7.0 million; +15% vs. 2Q 2019

    • 1H 2020 Afrezza Net Revenue of $15.0 million; +35% vs. 1H 2019
    • Cash and cash equivalents of $63.2 million at June 30, 2020
    • Non-GAAP cash used in operating activities decreased by 37% vs. 1H 2019
    • Chief Commercial Officer, Alejandro Galindo, joined MannKind

    WESTLAKE VILLAGE, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the quarter and six months ended June 30, 2020.

    "I am proud of how our employees pulled together during these uncertain times and innovated as a team to minimize the impact of the COVID-19 pandemic on our business during the second quarter," said Michael Castagna, Chief Executive Officer.  "A small 3% reduction in Afrezza TRx compared to the first quarter, when there was a bolus of prescriptions due to patient stockpiling, reflects the successful execution of our commercial plan in a new virtual environment.  We faced many challenges during this quarter, but whether it was production personnel ensuring Afrezza supply through the end of the year, the research team producing clinical supplies for our collaboration partner, United Therapeutics, the field force executing new sales tactics or home office staff adapting to a totally virtual environment, our team exceeded all expectations."

    Second Quarter 2020 Results

    Total revenues were $15.1 million for the second quarter of 2020, reflecting Afrezza net revenue of $7.0 million and collaboration and services revenue of $8.1 million. Afrezza net revenue increased 15% compared to $6.1 million in the second quarter of 2019, primarily driven by price, a favorable mix of cartridges and higher product demand. Collaboration and services revenue for the second quarter of 2020 decreased $0.8 million compared to the second quarter of 2019, primarily due to the substantial completion of the research agreement with United Therapeutics in the second quarter of 2019. 

    Afrezza gross profit for the second quarter of 2020 was $3.3 million vs. $1.7 million in the same period of 2019, a 90% increase that was driven primarily by higher Afrezza revenue combined with a reduction in cost of goods sold. Cost of goods sold decreased by $0.7 million, primarily due to $0.6 million in reduced spending. Gross margin in the second quarter of 2020 increased to 47% from 29% for the same quarter in 2019.

    Selling, general and administrative expenses for the second quarter of 2020 were $13.7 million compared to $16.6 million for the second quarter of 2019. This 18% decrease was primarily due to a $1.9 million reduction in promotional and marketing activities, a $0.5 million decrease in personnel related costs as well as a $0.2 million decrease in professional costs.

    Interest expense for the second quarter of 2020 was $2.4 million compared to $1.7 million for the second quarter of 2019. This $0.7 million increase was primarily attributable to a higher balance of outstanding principal.

    The net loss for the second quarter of 2020 was $10.3 million, or $0.05 per share, compared to a $12.4 million net loss in the second quarter of 2019, or $0.07 per share. The lower net loss is mainly attributable to a decrease in operating expenses of $2.9 million. The reduction in the net loss per share was impacted by both lower operating expenses and a greater number of outstanding shares.

    Six Months Ended June 30, 2020

    Total revenues were $31.3 million for the six months ended June 30, 2020, reflecting Afrezza net revenue of $15.0 million and collaboration and services revenue of $16.4 million. Afrezza net revenue increased 35% compared to $11.1 million for the six months ended June 30, 2019, primarily driven by higher product demand, a more favorable mix of Afrezza cartridges, price and a reduction in wholesaler channel inventory in the six months ended June 30, 2019. Collaboration and services revenue for the six months ended June 30, 2020 decreased $4.9 million compared to the six months ended June 30, 2019, primarily due to a $5.5 million decrease in revenue recognized from the UT Research Agreement, which was substantially completed in the second quarter of 2019, partially offset by a $0.6 million increase in revenue from the UT License Agreement.

    Afrezza gross profit for the six months ended June 30, 2020 was $7.1 million vs. $2.8 million in the same period of 2019, a 156% increase that was driven primarily by higher Afrezza revenue. Cost of goods sold decreased by $0.5 million, primarily attributable to $1.2 million of increased manufacturing activities, which resulted in a greater amount of costs capitalized to inventory and $0.6 million in reduced spending, partially offset by $0.9 million in costs associated with higher commercial product sales and $0.5 million of inventory write-offs. Gross margin for the six months ended June 30, 2020 increased to 48% from 25% for the same period in 2019, primarily due to higher Afrezza revenue.

    Selling, general and administrative expenses for the six months ended June 30, 2020 were $28.0 million compared to $42.3 million for the same period in 2019. This 34% decrease was primarily due to $9.3 million spent on direct-to-consumer television advertising in 2019 (which was not repeated in 2020), a $3.1 million decrease in promotional and marketing activities, a $1.2 million decrease in personnel and employee related costs and a $0.5 million decrease in consulting costs.

    Interest expense for the six months ended June 30, 2020 was $4.7 million compared to $3.3 million for the same period in 2019. This $1.4 million increase was primarily due to the borrowings under the MidCap Credit Facility in August 2019.

    The net loss for the six months ended June 30, 2020 was $19.6 million, or $0.09 per share, compared to a $27.3 million net loss for the same period in 2019, or $0.15 per share. The lower net loss is mainly attributable to a decrease in operating expenses of $10.5 million. The reduction in the net loss per share was impacted by both lower operating expenses and a greater number of outstanding shares.

    Cash, cash equivalents and restricted cash at June 30, 2020 was $63.5 million compared to $50.2 million at December 31, 2019, which also included short-term investments of $20.0 million. The increase was primarily due to the receipt of a $12.5 million United Therapeutics milestone payment, $12.2 million of net proceeds received from the at-the-market offering, $11.6 million received from warrant exercises and the origination of a Paycheck Protection Program loan for $4.9 million, offset by non-GAAP net cash used in operating activities of $27.4 million.

    Chief Commercial Officer

    As previously announced, Alejandro Galindo, M.B.A, M.S., joined the Company on August 4, 2020 as Chief Commercial Officer. Mr. Galindo has an accomplished track-record of over 25 years in the healthcare, energy, and consumer industries. He spent the past six years at Medtronic as Vice President and President of the Advanced Insulin Management Business Unit, where he led a fast-paced, double-digit growth global business within their diabetes division. Prior to Medtronic, Mr. Galindo spent nine years at General Electric (GE) Healthcare in a variety of leadership roles, leading emerging markets, strategic corporate development and global supply chain operations. Prior to joining GE's Healthcare division, he spent eleven years in various global leadership positions for the company's energy and appliance sectors, overseeing advanced manufacturing engineering and product development. Mr. Galindo received a B.Sc. in Industrial & Systems Engineering from Monterrey Institute of Technology, Mexico and M.B.A. and M.S. degrees from Indiana University.

    Non-GAAP Measures

    Certain financial information contained in this press release is presented on both a reported basis (GAAP) and a non-GAAP basis.  Reported results were prepared in accordance with GAAP whereas non-GAAP measures exclude items described in the reconciliation tables below.  Non-GAAP financial information is intended to portray the results of our baseline performance, supplement or enhance management, analysts and investors overall understanding of our underlying financial performance and facilitate comparisons among current and past periods.  The non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP.

      Six Months Ended June 30, 
      2020  2019  $ Change  % Change 
    Net cash used in operating activities $(14,903) $(31,325) $(16,422)   (52%)
    Exclude United Therapeutic milestone payment received  (12,500)  (12,500)      0%
    Non-GAAP cash used in operating activities $(27,403) $(43,825) $(16,422)   (37%)

    Conference Call

    MannKind will host a conference call and presentation webcast to discuss these results today at 5:00 p.m. Eastern Time. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at http://www.mannkindcorp.com under News & Events. 

    A telephone replay of the call will be accessible for approximately 14 days following completion of the call by dialing (844) 512-2921 or (412) 317-6671 and use the participant passcode: 7888638#. A replay will also be available on MannKind's website for 14 days.

    About MannKind Corporation

    MannKind Corporation (NASDAQ:MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide.  MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.

    Forward-Looking Statements

    This press release contains forward-looking statements that involve risks and uncertainties. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind's current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties detailed in MannKind's filings with the SEC, including risks related to the COVID-19 pandemic. For a discussion of these and other factors, please refer to MannKind's annual report on Form 10-K for the year ended December 31, 2019 as well as MannKind's other filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.

    Company Contact:

    818-661-5000



    MANNKIND CORPORATION AND SUBSIDIARY

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (Unaudited)

    (In thousands, except per share data)
     
      
      June 30, 2020  December 31, 2019 
    ASSETS        
    Current assets:        
    Cash and cash equivalents $63,222  $29,906 
    Restricted cash  316   316 
    Short-term investments     19,978 
    Accounts receivable, net  3,366   3,513 
    Inventory  3,823   4,155 
    Prepaid expenses and other current assets  1,856   2,889 
    Total current assets  72,583   60,757 
    Property and equipment, net  26,187   26,778 
    Other assets  4,011   6,190 
    Total assets $102,781  $93,725 
             
    LIABILITIES AND STOCKHOLDERS' DEFICIT        
    Current liabilities:        
    Accounts payable $5,821  $4,789 
    Accrued expenses and other current liabilities  14,706   15,904 
    Short-term notes payable  5,387   5,028 
    Deferred revenue — current  32,184   32,503 
    Recognized loss on purchase commitments — current  9,841   7,394 
    Total current liabilities  67,939   65,618 
    Promissory notes  70,024   70,020 
    Accrued interest — promissory notes  4,538   2,002 
    Long-term Midcap credit facility  39,304   38,851 
    Senior convertible notes  5,000   5,000 
    Paycheck Protection Program loan — long term  2,030    
    Recognized loss on purchase commitments — long term  81,027   84,639 
    Operating lease liability  1,843   2,514 
    Deferred revenue — long term  4,860   8,344 
    Milestone rights liability  5,926   7,263 
    Total liabilities  282,491   284,251 
             
    Stockholders' deficit:        
    Undesignated preferred stock, $0.01 par value — 10,000,000 shares

      authorized; no shares issued or outstanding as of June 30, 2020 and

      December 31, 2019
          
    Common stock, $0.01 par value - 400,000,000 and 280,000,000 shares

      authorized, 228,927,505 and 211,787,573 shares issued and outstanding

      at June 30, 2020 and December 31, 2019, respectively
      2,289   2,118 
    Additional paid-in capital  2,829,478   2,799,278 
    Accumulated other comprehensive loss     (19)
    Accumulated deficit  (3,011,477)  (2,991,903)
    Total stockholders' deficit  (179,710)  (190,526)
    Total liabilities and stockholders' deficit $102,781  $93,725 
             



    MANNKIND CORPORATION AND SUBSIDIARY

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

    (Unaudited)

    (In thousands, except per share data)
     
     Three Months Ended June 30,  Six Months Ended June 30, 
     2020  2019  2020  2019 
    Revenues:               
    Net revenue — commercial product sales$6,985  $6,065  $14,985  $11,141 
    Revenue — collaborations and services 8,129   8,937   16,364   21,309 
    Total revenues 15,114   15,002   31,349   32,450 
    Expenses:               
    Cost of goods sold 3,677   4,327   7,841   8,347 
    Cost of revenue — collaborations and services 1,983   2,139   5,345   3,676 
    Research and development 1,464   1,632   3,219   3,299 
    Selling, general and administrative 13,670   16,609   28,020   42,282 
    Asset impairment 368      1,889    
    Loss (gain) on foreign currency translation 1,867   1,247   71   (688)
    Total expenses 23,029   25,954   46,385   56,916 
    Loss from operations (7,915)  (10,952)  (15,036)  (24,466)
    Other (expense) income:               
    Interest income 14   255   147   573 
    Interest expense on notes (1,084)  (564)  (2,155)  (1,157)
    Interest expense on promissory notes (1,281)  (1,109)  (2,540)  (2,189)
    Other income (expense) 14   (17)  10   (31)
    Total other expense (2,337)  (1,435)  (4,538)  (2,804)
    Loss before provision for income taxes (10,252)  (12,387)  (19,574)  (27,270)
    Provision for income taxes           
    Net loss$(10,252) $(12,387) $(19,574) $(27,270)
    Net loss per share - basic and diluted$(0.05) $(0.07) $(0.09) $(0.15)
    Shares used to compute basic and diluted net loss per

      share
     213,880   188,054   212,943   187,744 
                    

    Primary Logo

    View Full Article Hide Full Article
  4. WESTLAKE VILLAGE, Calif., July 29, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2020 second quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday, August 5, 2020.

    Presenting from the Company will be its Chief Executive Officer, Michael Castagna and Chief Financial Officer, Steven Binder.

    Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at http://www.mannkindcorp.com under News & Events. 

    A telephone replay of the call will be accessible for approximately 14 days following completion of the call by dialing (844) 512-2921 or (412…

    WESTLAKE VILLAGE, Calif., July 29, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2020 second quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday, August 5, 2020.

    Presenting from the Company will be its Chief Executive Officer, Michael Castagna and Chief Financial Officer, Steven Binder.

    Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at http://www.mannkindcorp.com under News & Events. 

    A telephone replay of the call will be accessible for approximately 14 days following completion of the call by dialing (844) 512-2921 or (412) 317-6671 and use the participant passcode: 7888638#. A replay will also be available on MannKind's website for 14 days.

    About MannKind Corporation

    MannKind Corporation (NASDAQ:MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diabetes and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide.  MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.

    Company Contact:

    Phone: (818) 661-5000

    Email:

    Primary Logo

    View Full Article Hide Full Article
View All MannKind Corporation News